The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence

Abstract

Background and study aim Genetic polymorphisms may play a role in muscular injury associated with simvastatin, but results were inconclusive. This study aimed to summarize evidence from the literature investigating the effects of genetic polymorphism on simvastatin-induced myopathy.

Methods Studies regarding the association between genetic polymorphisms and simvastatin-induced myopathy were retrieved through electronic databases from February 1, 1990 to March 15, 2018. Two authors independently extracted data, including PMID, author, publication year, country, race, age, population characteristics, drugs, definition of case and control, gene, allele, SNP position, Hardy-Weinberg equilibrium, number of genotypes (case and control), minor allele frequency of cases and controls, association, study type and the Newcastle-Ottawa scale. Due to high heterogeneity in study design and outcome measurements among the included articles, a narrative synthesis of the evidence was conducted.

Results A total of 10 association studies were identified in this study, including SLCO1B1, ABCB1, GATM, HTR3B, HTR7, RYR2 and HLA-DRB1. The evidence linking myopathy to rs4149056 in SLCO1B1 is of high quality, and this association has been reproduced in randomized trials and clinical practice-based cohorts. As for other candidate genetic markers, the evidences are limited or controversial, and additional well-designed studies with larger sample sizes, are required to further elucidate this association.

Conclusion SLCO1B1 genotype is a useful biomarker for predicting an increased risk of simvastatin-induced myopathy.

Key words

simvastatin - genetic polymorphisms - myopathy - SLCO1B1 - evidences

• References

• 1 Taylor F, Huffman MD, Macedo AF. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; CD004816
• 2 Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: A study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390-399
• 3 Abd TT TT, Jacobson TA. Statin-induced myopathy: A review and update. Expert Opin Drug Saf 2011; 10: 373-387
• 4 Pasanen MK, Neuvonen M, Neuvonen PJ. et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16: 873-879
• 5 Group SC, Link E, Parish S. et al. SLCO1B1 variants and statin-induced myopathy--A genomewide study. N Engl J Med 2008; 359: 789-799
• 6 Ramsey LB, Johnson SG, Caudle KE. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014; 96: 423-428
• 7 Voora D, Shah SH, Spasojevic I. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54: 1609-1616
• 8 Brunham LR, Lansberg PJ, Zhang L. et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012; 12: 233-237
• 9 Tsamandouras N, Dickinson G, Guo Y. et al. Development and application of a mechanistic pharmacokinetic model for simvastatin and its active metabolite simvastatin acid using an integrated population PBPK approach. Pharm Res 2015; 32: 1864-1883
• 10 Fiegenbaum M, da Silveira FR, Van der Sand CR. et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78: 551-558
• 11 Becker ML, Visser LE, van Schaik RH. et al. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 75-81
• 12 Mangravite LM, Engelhardt BE, Medina MW. et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013; 502: 377-380
• 13 Luzum JA, Kitzmiller JP, Isackson PJ. et al. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell Metab 2015; 21: 622-627
• 14 Ruano G, Thompson PD, Windemuth A. et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007; 36: 329-335
• 15 Marciante KD, Durda JP, Heckbert SR. et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011; 21: 280-288
• 16 Hubacek JA, Adamkova V, Hruba P. et al. Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. Eur J Intern Med 2015; 26: 367-368
• 17 Sai K, Kajinami K, Akao H. et al. A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab Pharmacokinet 2016; 31: 467-470
• 18 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605
• 19 Abe T, Kakyo M, Tokui T. et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159-17163
• 20 Takeda M, Noshiro R, Onozato ML. et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 2004; 483: 133-138
• 21 Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004; 61: 682-699
• 22 Joncquel-Chevalier Curt M, Voicu PM, Fontaine M. et al. Creatine biosynthesis and transport in health and disease. Biochimie 2015; 119: 146-165
• 23 Mareedu RK, Modhia FM, Kanin EI. et al. Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev Cardiol 2009; 12: 88-94
• 24 Xiao J, Tian X, Jones PP. et al. Removal of FKBP12.6 does not alter the conductance and activation of the cardiac ryanodine receptor or the susceptibility to stress-induced ventricular arrhythmias. J Biol Chem 2007; 282: 34828-34838
• 25 Davies PA, Pistis M, Hanna MC. et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999; 397: 359-363
• 26 Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-554
• 27 Ranasinghe S, Cutler S, Davis I. et al. Association of HLA-DRB1-restricted CD4(+) T cell responses with HIV immune control. Nat Med 2013; 19: 930-933
• 28 Tirona RG, Leake BF, Merino G. et al. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669-35675
• 29 Kameyama Y, Yamashita K, Kobayashi K. et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 15: 513-522
• 30 Pasanen MK, Fredrikson H, Neuvonen PJ. et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82: 726-733
• 31 Thompson JF, Man M, Johnson KJ. et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5: 352-358
• 32 Mwinyi J, Johne A, Bauer S. et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75: 415-421
• 33 Rodrigues AC, Perin PM, Purim SG. et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci 2011; 12: 5815-5827
• 34 Fu Q, Li YP, Gao Y. et al. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013; 69: 1269-1274
• 35 Prado Y, Saavedra N, Zambrano T. et al. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci 2015; 16: 20609-20619
• 36 Kadam P, Ashavaid TF, Ponde CK. et al. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther 2016; 41: 329-333
• 37 Wen JXiong Y. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 2010; 35: 99-104
• 38 Wang D, Johnson AD, Papp AC. et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704
• 39 Leschziner GD, Andrew T, Pirmohamed M. et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: A critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154-179
• 40 Kajinami K, Brousseau ME, Ordovas JM. et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004; 93: 1046-1050
• 41 Keskitalo JE, Pasanen MK, Neuvonen PJ. et al. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009; 10: 1617-1624
• 42 Srinivas NR. Limited sampling strategy for the prediction of area under the curve (AUC) of statins: Reliability of a single time point for auc prediction for pravastatin and simvastatin. Drug Res (Stuttg) 2016; 66: 82-93
• 43 Alaei M, Najmi AK, Kausar H. et al. A prospective research study of anti-glaucoma drugs prescribing, utilization pattern and adverse drug reaction recording in a university hospital. Drug Res (Stuttg) 2015; 65: 164-168